
Quick Facts
Hepatitis B
- Hepatitis B (HBV) is a viral infection that infects the liver and requires direct contact with infected blood or other body fluids for transmission.1 Most acute hepatitis B infections last several weeks but, in some cases, they can last for up to 6 months.2 Individuals who recover from an acute hepatitis B infection and clear the virus are immune for life.3 If the infection lasts 6 months or longer and becomes chronic, it can lead to serious health problems including chronic liver disease, liver cancer, and death.4
- According to the U.S. Centers for Disease Control and Prevention (CDC) occurs largely in adults and infection is most often transmitted through sexual contact, sharing of needles, syringes and other drug injection equipment.5 Most infections are without any symptoms. Symptoms include yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain.6
- In the U.S., hepatitis B is primarily an adult disease, with most cases occurring in persons between 40 and 49 years of age.7 The virus can also be transmitted from an infected mother to her newborn baby,8 however, newborn infections are rare in the U.S. due to routine screening of all women during pregnancy.9 10 Screening determines whether the mother has an acute or chronic hepatitis B infection that may be transmitted to the newborn during the delivery and allows for treatments to be made available to reduce the risk of newborn infection.11 12 Without treatment at birth, up to 90 percent of infants born to hepatitis B infected mothers may go on to develop chronic hepatitis B infection.13 In 2019, the CDC reported only 19 hepatitis B infections from transmission between an infected mother and her newborn baby during childbirth.14
- Populations at highest risk for infection include illegal IV drug users, prostitutes, men who have sex with men, individuals with multiple sexual partners, and people receiving hemodialysis.15 Healthcare workers exposed to infected blood or body fluids of patients through contact with needles or medical devices used on patients, or when breaches in proper hygiene and/or infection control practices occur, are also at high risk for becoming infected.16
- Worldwide, hepatitis B is the cause of up to 80 percent of liver cancer17 and an estimated 820,000 people die each year from acute or chronic hepatitis B,18 and is historically endemic in Asia and Africa. Prior to U.S. vaccination campaigns introduced in 1991, hepatitis B was not prevalent in the U.S., with only 18,003 cases of hepatitis B reported, representing .00007 percent of the total U.S population. In 1996, 10,637 cases of hepatitis B were reported in the U.S. with 279 cases reported in children under the age of 14.19 By 2020, there were 2,157 acute cases of hepatitis B reported in the U.S.20
Hepatitis B Vaccine
- There are seven recombinant hepatitis B vaccines approved by the FDA for use in the U.S.: Engerix-B; Recombivax HB; Twinrix (combined with hepatitis A); Pediarix, a 5 in 1 combination vaccine containing diphtheria and tetanus toxoids, acellular pertussis adsorbed, and inactivated poliovirus; VAXELIS, a 6 in 1 combination vaccine containing diphtheria and tetanus toxoids, acellular pertussis adsorbed, inactivated poliovirus, hepatitis B recombinant, and Hib conjugate vaccine; HEPLISAV-B; and PREHEVBRIO.21 HEPLISAV-B, approved for use in adults 18 years and older, is a recombinant adjuvanted vaccine created through genetic engineering of DNA by inserting a segment of the viral gene in a yeast cell.22 This vaccine contains the CpG 1018 adjuvant which has not been previously used in any vaccine licensed in the U.S.23 PREHEVBRIO, approved by the FDA in 2020 for use in persons 18 and older, targets all known hepatitis B subtypes and is produced using Chinese hamster ovary cells.24
- According to the package insert for hepatitis B vaccines, side effects include redness, warmth, or swelling at the injection site and fever over 99.9 degrees F may occur and can last one to two days. Systemic reactions include irritability, diarrhea, fatigue, weakness, diminished appetite and rhinitis.25 26 27 28 29 30 31 Serious side effects from hepatitis B vaccine, however, have been reported to both the federal Vaccine Adverse Events Reporting System (VAERS), and in the medical literature, including lupus,32 arthritis,33 34 35 Guillain Barre Syndrome (GBS),36 demyelinating disorders such as optic neuritis, Bell’s palsy, transverse myelitis, demyelinating neuropathy and multiple sclerosis,37 38 39 40 41 diabetes,42 chronic fatigue syndrome,43 vascular disorders, and more.44 45 Animal reproduction studies have not been conducted on hepatitis B vaccines and it is unknown whether the vaccine can cause fetal harm or affect reproduction. They have also not been studied for carcinogenic or mutagenic potential, or for their potential to impair fertility. 46 47 48 49 50 51 52
- In 1991, the CDC recommended hepatitis B vaccination for all newborns in the U.S. because public health officials and doctors could not persuade adults in high risk groups (primarily IV drug users and persons with multiple sexual partners) to get the vaccine.53 54 55
- The CDC recommends 3 doses of hepatitis B vaccine by 6 months of age, regardless of maternal infection status. Infants weighing 4.4 lbs and greater receive the first dose within 24 hours of birth, with those weighing less than 4.4 lbs delaying vaccination until hospital discharge or one month of age. Infants born to infected mothers are recommended to receive hepatitis B vaccine, along with hepatitis B immune globulin (HBIG) within 12 hours of birth.56 The CDC also recommends hepatitis B vaccination for all adults aged 18 through 59 years, and for adults aged 60 and older with known risk factors for hepatitis B.57
- Despite hepatitis B affecting mainly adults (aged 30 to 59),58 by 2018, only 30 percent of U.S. adults over 19 years of age had received the vaccine. Only 67.2 percent of U.S. health care workers in 2018 had been vaccinated for hepatitis B.59
- Using the MedAlerts search engine, as of the January 2, 2026 data release, there have been 113,844 adverse events reported to the federal Vaccine Adverse Events Reporting System (VAERS) in connection with hepatitis B containing vaccines. Nearly 56 percent (61,451) of reported serious hepatitis B vaccine-related adverse events occurred in children under 3 years old, with over 70 percent (1,774) of deaths occurring in children under three years of age. Out of the reports in VAERS there were 2,459 related deaths, 17,209 hospitalizations, and 3,829 related disabilities.
- As of December 1, 2025, there had been 1,064 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following hepatitis B containing vaccinations, including 106 deaths and 958 serious injuries.
Food & Drug Administration (FDA)
- Recombinant Hepatitis B Vaccine Product Insert and Licensing Information
- Adjuvanted Recombinant Hepatitis B Vaccine Product Insert and Licensing Information
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined Product Insert and Licensing Information
- Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine Product Insert and Licensing Information
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine Vaccine Product Insert and Licensing Information
Search for Vaccine Reactions
NVIC hosts MedAlerts, a powerful VAERS database search engine. MedAlerts examines symptoms, reactions, vaccines, dates, places, and more.
Reporting a Vaccine Reaction
Since 1982, the NVIC has operated a Vaccine Reaction Registry, which has served as a watchdog on VAERS. Reporting vaccine reactions to VAERS is the law. If your doctor will not report a reaction, you have the right to report a suspected vaccine reaction to VAERS.
Vaccine Reaction Symptoms & Ingredients
Our Ask 8, If You Vaccinate webpage contains vaccine reaction symptoms and more.
Centers for Disease Control (CDC)
- CDC on Hepatitis B
- CDC on Hepatitis B Vaccination
- Hepatitis B Vaccine Information Sheet (VIS)
- Your Child’s First Vaccines Vaccine Information Sheet (VIS)
- State Screening Requirements for Pregnant Women
IMPORTANT NOTE: NVIC encourages you to become fully informed about Hepatitis B and the Hepatitis B vaccine by reading all sections in the Table of Contents , which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.
References:
- 1 US Centers for Disease Control and Prevention. How is HBV transmitted?. Mar. 30, 2022.
- 2 US Centers for Disease Control and Prevention. When symptoms of acute hepatitis B occur, how long do they usually last?. Mar. 30, 2022.
- 3 US Centers for Disease Control and Prevention. If I have been infected with the hepatitis B virus in the past, can I get it again?. Mar. 30, 2022.
- 4 US Centers for Disease Control and Prevention. Hepatitis B. Oct. 12, 2021.
- 5 Mayo Clinic. Symptoms and Causes. Sept. 24, 2022.
- 6 Communication and Education Branch, National Center for Immunization and Respiratory Diseases (NCIRD) and the Centers for Disease Control (CDC). Hepatitis B. 13th ed. Centers for Disease Control (CDC) Aug. 18, 2021.
- 7 Communication and Education Branch, National Center for Immunization and Respiratory Diseases (NCIRD) and the Centers for Disease Control (CDC). Hepatitis B. 13th ed. Centers for Disease Control (CDC) Aug. 18, 2021.
- 8 US Centers for Disease Control and Prevention. Hepatitis B Transmission. Mar. 30, 2022.
- 9 Ko SC, Fan L, Smith EA, et al. Estimated Annual Perinatal Hepatitis B Virus Infections in the United States, 2000-2009. J Pediatric Infect Dis Soc June 5, 2016; 5(2):114-121.
- 10 US Centers for Disease Control and Prevention. Screening Recommendations. Aug. 11, 2022.
- 11 Ko SC, Fan L, Smith EA, et al. Estimated Annual Perinatal Hepatitis B Virus Infections in the United States, 2000-2009. J Pediatric Infect Dis Soc June 5, 2016; 5(2):114-121.
- 12 US Centers for Disease Control and Prevention. Screening Recommendations. Aug. 11, 2022.
- 13 Nelson, NP Jamieson DJ & Murphy TV. Prevention of Perinatal Hepatitis B Virus Transmission. J Pediatric Infect Dis Soc 2014.
- 14 US Centers for Disease Control and Prevention. TABLE 2h. Annual reported cases of notifiable diseases, by region and reporting area, United States and U.S. Territories, excluding Non-U.S. Residents*, 2019.
- 15 US Centers for Disease Control and Prevention. Who is at risk for HBV infection?. Mar. 30, 2022.
- 16 Wassem, M. Body Fluid Exposures. Medscape Jun. 19, 2019.
- 17 Hep. Liver Cancer and Hepatitis B. May 22, 2019.
- 18 World Health Organization. Hepatitis B. June 24, 2022.
- 19 US Centers for Disease Control and Prevention. Summary of Notifiable Diseases, United States 1996. Table 2 – Notifiable Diseases – Summary of reported cases, United States 1991 and 1996. MMWR Oct. 31, 1997; 45(53): 1-89.
- 20 US Centers for Disease Control and Prevention. Hepatitis B Surveillance Report 2020. Aug. 19, 2022.
- 21 US Food and Drug Administration. Vaccines Licensed for Use in the United States. July 5, 2022.
- 22 Communication and Education Branch, National Center for Immunization and Respiratory Diseases (NCIRD) and the Centers for Disease Control (CDC). Principles of Vaccination. 13th ed. Centers for Disease Control (CDC) Aug. 18, 2021.
- 23 Major M. Hepatitis B Vaccine (Recombinant), Adjuvanted (HBV Surface Antigen (HBsAg) Protein with CpG 1018 adjuvant). U.S. Food and Drug Administration.
- 24 VBI Vaccines (Delaware) Inc. Package Insert – PREHEVBRIO. U.S. Food and Drug Administration Dec. 13, 2021.
- 25 Merck & Co, Inc. Package Insert – Recombivax HB. U.S. Food and Drug Administration Apr. 24, 2019.
- 26 GlaxoSmithKline Biologicals. Package Insert – Engerix-B. U.S. Food and Drug Administration Oct. 3, 2019.
- 27 GlaxoSmithKline Biologicals. Package Insert – TWINRIX. U.S. Food and Drug Administration Oct. 3, 2019.
- 28 GlaxoSmithKline Biologicals. Package Insert – PEDIARIX. U.S. Food and Drug Administration Oct. 2, 2019.
- 29 MSP Vaccine Company. Package Insert – VAXELIS. U.S. Food and Drug Administration Oct. 29, 2020.
- 30 Dynavax Technologies Corporation. Package Insert – HEPLISAV-B. U.S. Food and Drug Administration May 6, 2020.
- 31 VBI Vaccines (Delaware) Inc. Package Insert – PREHEVBRIO. U.S. Food and Drug Administration Dec. 13, 2021.
- 32 Agmon-Levin, N. Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus Nov. 2009.
- 33 Maillefert, JF, Sibilia J, Toussirot E, et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology (Oxford) 1999 Oct; 38(10):978-83.
- 34 Hachulla E, Houvenagel E, Mingui A, et al. Reactive arthritis after hepatitis B vaccination. J Rheumatol Sept. 1990; 17(9):1250–1251.
- 35 Maillefert J. Vaccination and rheumatoid arthritis. Ann Rheum Dis July 2002; 61(7): 575–576.
- 36 Khamaisi M, Shoenfeld Y, Orbach H. Guillain-Barré syndrome following hepatitis B vaccination. Clin Exp Rheumatol Dec 2004; 22(6):767-70.
- 37 Shaw FE JR, Graham DJ, Guess HA et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. Am J Epidemiol Feb 1988; 127(2):337-52.
- 38 Herroelen L, de Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet Nov. 9, 1991; 338(8776):1174-5.
- 39 Nadler, JP,. Multiple sclerosis and hepatitis B vaccination. Clin Infect Dis Nov. 1993; 17(5):928-9.
- 40 Kaplanski G, Retornaz F, Durand J. Central nervous system demyelination after vaccination against hepatitis B and HLA haplotype. J Neurol Neurosurg Psychiatry June 1995; 58(6): 758–759.
- 41 Alp H, Tan H, Orbak Z. Bell’s Palsy as a Possible Complication of Hepatitis B Vaccination in A Child. J Health Popul Nutr. Oct 2009; 27(5): 707–708.
- 42 Classen, JB. Clustering of Cases of IDDM 2 to 4 Years after Hepatitis B Immunization is Consistent with Clustering after Infections and Progression to IDDM in Autoantibody Positive Individuals. The Open Pediatric Medicine Journal 2: 1-6.
- 43 Agmon-Levin N, Zafrir Y, Kivity S et al. Chronic fatigue syndrome and fibromyalgia following immunization with the hepatitis B vaccine: another angle of the ‘autoimmune (auto-inflammatory) syndrome induced by adjuvants’ (ASIA). Immunol Res Dec. 2014.
- 44 Goolsby PL. Erythema nodosum after Recombivax HB Hepatitis B vaccine. N Engl J Med Oct 26, 1989; 321(17):1198-9.
- 45 Cockwell P. Vasculitis related to hepatitis B vaccine. BMJ Dec 1, 1990.
- 46 Merck & Co, Inc. Package Insert – Recombivax HB. U.S. Food and Drug Administration Apr. 24, 2019.
- 47 GlaxoSmithKline Biologicals. Package Insert – Engerix-B. U.S. Food and Drug Administration Oct. 3, 2019.
- 48 GlaxoSmithKline Biologicals. Package Insert – TWINRIX. U.S. Food and Drug Administration Oct. 3, 2019.
- 49 GlaxoSmithKline Biologicals. Package Insert – PEDIARIX. U.S. Food and Drug Administration Oct. 2, 2019.
- 50 MSP Vaccine Company. Package Insert – VAXELIS. U.S. Food and Drug Administration Oct. 29, 2020.
- 51 Dynavax Technologies Corporation. Package Insert – HEPLISAV-B. U.S. Food and Drug Administration May 6, 2020.
- 52 VBI Vaccines (Delaware) Inc. Package Insert – PREHEVBRIO. U.S. Food and Drug Administration Dec. 13, 2021.
- 53 Kasper D, Fauci A, Longo D, et al. 16th Edition. 2005. Harrison’s Principles of Internal Medicine.
- 54 Viral Hepatitis Prevention Board. Control of viral hepatitis in Europe.
- 55 US Centers for Disease Control and Prevention. Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States through Universal Childhood Vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Nov. 22, 1991.
- 56 Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Jan. 12, 2018; 67(1):1–31.
- 57 Weng MK, Doshani M, Khan MA, et al. Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Apr. 1, 2022; 71:477–483.
- 58 US Centers for Disease Control and Prevention. Hepatitis B Surveillance Report 2020. Aug. 19, 2022.
- 59 Lu PJ, Hung MC, Srivastav A. Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018. MMWR May 14, 2021; 70(3):1-26.